GLP-1s are not just another diabetes medication
Milligrams (mg) is not an amount of liquid, but rather the amount of drug that is within
Discrete choice experiments can formalize the trade-offs patients and clinicians routinely makebetween expected weight loss, chances of conception, adverse effects, out-of-pocket costs, and the possibility of post-discontinuation regainso that Evidence-to-Decision processes can incorporate empirically derived weights rather than implicit assumptions
Safety risks in the GLP-1 market: an update on weight loss medication, May 2026 Drug shortages and coverage gaps have led to criminal counterfeiters exploiting Americans demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide
Full Plate Living is a small-step approach with big health outcomes
Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
